Protocol Details

Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number	18-C-0017
Sponsoring Institute	National Cancer Institute (NCI)
Recruitment Detail	Type: Participants currently recruited/enrolled Gender: Male Min Age: 18 Years Max Age: N/A
Referral Letter Required	No
Population Exclusion(s)	Children; Female
Keywords	Imaging-Based Prognostic Markers; Multiparametric MRI (mpMRI); Translation of Imaging into Treatment Decisions; Decision-Support System; Artificial Intelligence Research; Natural History
Recruitment Keyword(s)	None
Condition(s)	Prostatic Cancer; Prostatic Neoplams; Prostatic Hyperplasia; Prostate Cancer; Cancer Of Prostate
Investigational Drug(s)	None
Investigational Device(s)	None
Intervention(s)	None
Supporting Site	National Cancer Institute

Background:

Prostate cancer is one of the most common cancers for men in the U.S. There are some new ways to take pictures of the cancer. There are also new ways to use image-guided biopsy and therapy. These could help manage prostate cancer. Researchers want to study how imaging can provide a profile of prostate cancer. They want to collect data to make diagnosis and treatments better.

Objectives:

To gather data about the radiological and clinical course of prostate cancer. To study imaging-based biomarkers of prostate cancer.

Eligibility:

Men ages 18 and older with diagnosed or suspected prostate cancer

Design:

Participants will give permission for researchers to use their medical history and records. Their data will be reviewed, collected, and analyzed. These include results of their tests and scans.

Sponsoring Institution: National Cancer Institute

--Back to Top--

Eligibility

INCLUSION CRITERIA:

- Patients with an increased risk for prostate cancer (strong family history and/or germline mutation in DNA repair genes), or with a diagnosis of prostatic cancer or suspicious for prostatic cancer lesions.

- Age greater than or equal to 18 years

- Ability of subject to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

-none

--Back to Top--

Citations:

Toth R, Sperling D, Madabhushi A. Quantifying Post- Laser Ablation Prostate Therapy Changes on MRI via a Domain-Specific Biomechanical Model: Preliminary Findings. PLoS One. 2016 Apr 18;11(4):e0150016. doi: 10.1371/journal.pone.0150016. eCollection 2016.

Wang S, Burtt K, Turkbey B, Choyke P, Summers RM. Computer aided-diagnosis of prostate cancer on multiparametric MRI: a technical review of current research. Biomed Res Int. 2014;2014:789561. doi: 10.1155/2014/789561. Epub 2014 Dec 1.

Lavery HJ, Cooperberg MR. Clinically localized prostate cancer in 2017: A review of comparative effectiveness. Urol Oncol. 2017 Feb;35(2):40-41. doi: 10.1016/j.urolonc.2016.11.013. Epub 2016 Dec 18.

--Back to Top--

Contacts:

Principal Investigator	Referral Contact	For more information:
Ismail B. Turkbey, M.D. National Cancer Institute (NCI) NIHBC 10 - CLINICAL CENTER BG RM B3B85 10 CENTER DR BETHESDA MD 20892 (240) 760-6112 turkbeyi@mail.nih.gov	Yolanda McKinney, R.N. National Cancer Institute (NCI) National Institutes of Health Building 10 Room B3B69E 10 Center Drive Bethesda, Maryland 20892 (240) 760-6095 ymckinney@mail.nih.gov	NCI Referral Office National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office 1-888-NCI-1937 ncimo_referrals@mail.nih.gov

Clinical Trials Number:

NCT03354416

--Back to Top--